nct_id: NCT03383458
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2017-12-26'
study_start_date: '2018-04-18'
study_completion_date: ''
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Biological: Nivolumab'
  - drug_name: 'Other: Placebo'
long_title: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus
  Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence
  After Curative Hepatic Resection or Ablation
last_updated: '2023-11-18'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE3
principal_investigator: NA, Stephen Chan
principal_investigator_institution: Bristol-Myers Squibb, CUHK
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids:
- HCC055
protocol_no: ''
protocol_target_accrual: 545
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Participants with a first diagnosis of HCC who have undergone a curative resection
  or ablation'
- '* Participants are eligible to enroll if they have non-viral related-HCC, or if
  they have HBV-HCC, or HCV-HCC'
- '* Child-Pugh Score 5 or 6'
- '* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1'
- 'Exclude - Exclusion Criteria:'
- Exclude - * Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma
  and HCC
- Exclude - * Any evidence of tumor metastasis or co-existing malignant disease
- Exclude - * Participants previously receiving any prior therapy for HCC, including
  loco-regional therapies
- Exclude - * Participants who have undergone a liver transplant or those who are
  in the waiting list for liver transplantation
- Exclude - * Participants who have received a live/attenuated vaccine within 30 days
  of randomization (eg, varicella, zoster, yellow fever, rotavirus, oral polio and
  measles, mumps, rubella \[MMR\]).
- Exclude - Other protocol defined inclusion/exclusion criteria apply
short_title: A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who
  Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Bristol-Myers Squibb
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: This study will investigate if nivolumab will improve recurrence-free survival
  (RFS) compared to placebo in participants with HCC who have undergone complete resection
  or have achieved a complete response after local ablation, and who are at high risk
  of recurrence
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Arm A
      arm_internal_id: 0
      arm_description: Arm A
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Biological: Nivolumab'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Arm B
      arm_internal_id: 1
      arm_description: Arm B
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Other: Placebo'
        level_internal_id: 0
        level_suspended: N
    match:
    - and:
      - or:
        - clinical:
            oncotree_primary_diagnosis: Hepatocellular Carcinoma plus Intrahepatic
              Cholangiocarcinoma
        - clinical:
            oncotree_primary_diagnosis: Hepatocellular Carcinoma
        - clinical:
            oncotree_primary_diagnosis: Hepatoblastoma
        - clinical:
            oncotree_primary_diagnosis: Fibrolamellar Carcinoma
      - clinical:
          age_numerical: '>=18'
          disease_status:
          - Localized
